Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 2

WCLC Updates on the Emergence of ADCs in NSCLC

February 26, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Sarah Goldberg, MD, MPH, Yale School of Medicine

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Heather A. Wakelee, MD, Stanford University Medical Center

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

Data from the following clinical trials are discussed:

  • OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
  • OA03.04 - Efficacy and Safety of the Novel HER3-Directed Antibody-Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
  • OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study